期刊文献+

CXC族趋化因子5在肝癌细胞中的表达及其作用 被引量:6

Expression and role of CXC chemokine 5 in liver cancer cells
原文传递
导出
摘要 目的探讨CXC族趋化因子(CXCL)5在肝癌细胞中的表达及其对细胞增殖、迁移和侵袭的影响。方法利用实时定量PCR(RT—PCR)和酶联免疫吸附试验(ELISA)分别检测4种转移潜能依次递增的肝癌细胞(HepG2、SMMC7721、MHCC97L和MHCC97H)中CXCL5的mRNA和蛋白水平;选取低表达CXCL5的HepG2细胞为实验对象,接受外源性CXCL5刺激;实验分4组:CXCL5浓度分别为0、0.1、1.0、10.0nmol/L;利用细胞计数试剂盒(CCK-8)法检测细胞增殖情况;利用Transwell小室和基质胶观察CXCL5对细胞迁移和侵袭的影响。采用SPSS16.0统计软件进行数据分析,多组均数之间比较采用单因素方差分析(ANOVA),两两比较采用LSD检验。结果HepG2、SMMC7721、MHCC97L和MHCC97H中CXCL5的mRNA相对表达量分别为:0.002%±0.000%、0.005%±0.000%、1.030%±0.070%、0.980%±0.190%(F=33.88,P〈0.01);蛋白分泌量分别为:14.3±0.4、25.7±1.4、82.8±3.2、98.94-1.7(F:447.08,P〈0.01)。CCK-8结果示细胞增殖随CXCL5浓度升高而增强,但差异无统计学意义(F〈1.00,P〉0.05);0、0.1、1.0、10.0nmol/L组迁移细胞数分别为(29±3)、(56±16)、(113±7)、(130±15)个(F=51.94,P〈0.01);侵袭细胞数分别为(17.3±1.8)、(33.0±3.2)、(65.7±4.4)、(94.3±3.5)个(F=104.13,P〈0.01)。结论转移潜能高的肝癌细胞能够高表达CXCL5;转移潜能低的肝癌细胞在受到外源性CXCL5刺激后,细胞增殖、迁移和侵袭能力均升高,提示CXCL5可能与肝癌的转移有关。 Objective To explore the expression of CXC chemokine 5 (CXCL5) in liver cancer cells and its effect on cell proliferation, migration and invasion. Methods Real-time (RT)-PCR and enzyme-linked immunosorbent assay (ELISA) were used to detect the mRNA and protein levels of CXCL5 in 4 liver cancer cell lines with different metastatic potentials (in ascending order: HepG2, SMMC7721, MHCC97L and MHCC97H). HepG2 with a low expression of CXCL5 was treated with CXCL5. There were four groups : 0 nmol/L CXCL5, 0. 1 nmol/L CXCL5, 1.0 nmol/L CXCL5 and 10. 0 nmol/L CXCL5. Cell proliferation was evaluated by cell counting kit-8 (CCK-8) assay. Transwell chambers and basement membrane matrix (Matrigel) were used to observe the cellular migration and invasion. Statistical analysis was performed with SPSS 16.0. Statistical comparison of the results was made by analysis of variance (ANOVA). Results The relative mRNA expression levels of CXCL5 in HepG2, SMMC7721, MHCC97L and MHCC97H were 0.002% ±0.000%, 0.005% ± 0.000%, 1.030% ±0.070% and 0.980% ± 0. 190% ( F = 33.88, P 〈 0.01 ) while their protein levels 14. 3 ± 0. 4, 25.7 ± 1.4, 82. 8 ± 3.2 and 98. 9 ± 1.7 respectively (F =447. 08, P 〈 0. 01 ). The CCK-8 results showed that cell proliferation increased with the treatment of CXCL5, but no significant difference existed ( F 〈 1.00, P 〉 0. 05 ) , cell numbers of migration of 0, 0.1, 1.0, 10.0 nmol/L CXCL5 groups were 29 ± 3, 56 ± 16, 113 ± 7 and 130 ± 15 ( F = 51.94, P 〈 0. 01 ), while cell numbers of invasion 17. 3 ± 1.8, 33.0± 3.2, 65.7 ± 4. 4 and 94. 3 ± 3.5 respectively ( F = 104. 13, P 〈 0. 01 ). Conclusions Liver cancer cells with high metastatic potential have a higher expression of CXCL5. And exogenous CXCL5 can increase the proliferation, migration and invasion of liver cancer cells with low metastatic potential. Thus CXCL5 may be associated with the metastasis of liver cancer.
出处 《中华医学杂志》 CAS CSCD 北大核心 2012年第38期2716-2719,共4页 National Medical Journal of China
关键词 肝细胞 细胞运动 肿瘤侵润 趋化因子 CXC Carcinoma, hepatocellular Cell movement Neoplasm invasiveness Chemokines, CXC
  • 相关文献

参考文献10

  • 1Strieter RM, Polverini PJ, Kunkel SL, et al. The functional roleof the ELR motif in CXC chemokine-mediated angiogenesis. J BiolChem, 1995,270:27348-27357. 被引量:1
  • 2王琪,张玮,黎丹戎,李力.两种卵巢恶性肿瘤潜在血清标记物的纯化鉴定及临床验证[J].中华医学杂志,2008,88(15):1012-1016. 被引量:10
  • 3Park JY, Park KH, Bang S, et al. CXCL5 overexpression isassociated with late stage gastric cancer. J Cancer Res Clin Oncol,2007,133:835-840. 被引量:1
  • 4Begley LA, Kasina S, Mehra R, et al. CXCL5 promotes prostatecancer progression. Neoplasia, 2008,10 :244-254. 被引量:1
  • 5Kawamura M, Toiyama Y, Tanaka K, et al. CXCL5, a promoterof cell proliferation, migration and invasion, is a novel serumprognostic marker in patients with colorectal cancer[ J/OL] . Eur JCancer, 2011 [2012-04-08 ]. http://www. ejcancer. info/article/S0959-8049( 11) 00995-6/fulltext . [ published online ahead ofprint Decmber 26 , 2011 ]. 被引量:1
  • 6Li A, King J,Moro A, et al. Overexpression of CXCL5 isassociated with poor survival in patients with pancreatic cancer.Am J Pathol, 2011, 178: 1340-1349. 被引量:1
  • 7Walz A, Burgener R,Car B,et al. Structure and neutrophil-activating properties of a novel inflammatory peptide ( ENA-78 )with homology to interleukin 8. J Exp Med, 1991,174:1355-1362. 被引量:1
  • 8Okabe H, Beppu T, Ueda M, et al. Identification of CXCL5/ENA-78 as a factor involved in the interaction betweencholangiocarcinoma cells and cancer-associated fibroblasts [ J/OL]. Int J Cancer, 2012 [ 2012-04-08 ]. http ://onlinelibrary.wiley. com/doi/10. 1002/ijc. 27496/full [ pubilished online aheadof print March 27,2012]. 被引量:1
  • 9Speetjens FM, Kuppen PJ, Sandel MH, et al. Disruptedexpression of CXCL5 in colorectal cancer is associated with rapidtumor formation in rats and poor prognosis in patients. Clin CancerRes, 2008, 14:2276-2284. 被引量:1
  • 10Kuo PL, Chen YH, Chen TC,et al. CXCL5/ENA78 increasedcell migration and epithelial-to-mesenchymal transition of honnone-independent prostate cancer by early growth response-l/snailsignaling pathway. J Cell Physiol, 2011, 226: 1224-1231. 被引量:1

二级参考文献8

  • 1王琪,李力,黎丹戎,张伟,韦霄,张洁清,唐勇.应用飞行时间质谱技术结合蛋白芯片筛选卵巢恶性肿瘤患者的血清标志物[J].中华妇产科杂志,2006,41(8):544-548. 被引量:33
  • 2吴江宏,王亚农,欧周罗,师英强.胃癌患者术前外周血CCL18的检测及其意义[J].中国癌症杂志,2006,16(10):835-837. 被引量:9
  • 3Judith YMNE, Marie-Chrlstine WG, Jan HMS, et al. Clinical proteomics: searching for better turnout markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci, 2006, 27: 251-259. 被引量:1
  • 4Zhang Z, Bast BC, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res, 2004, 15: 5882-5890. 被引量:1
  • 5Kodera M, Hasegawa M, Komura K, et al. Serum pulmonary and activation regulated chemokine /CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum, 2005, 52 : 2889-2896. 被引量:1
  • 6StruyfS, Schutyser E, Gouwy M, et al. CCL18 /CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia. Am J Pathol, 2003, 163 : 2065-2075. 被引量:1
  • 7Leung SY, Yuen ST, Chu KM, et al. Expression profiling identifies chemokine (C2C motif) ligand 18 as an independent prognostic indicator in gastric cancer. Gastroenterology, 2004, 127 : 457-469. 被引量:1
  • 8Schutyser E, Struyf S, Proost P, et al. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18 /pulmonary and activation2regulated chemokine in ovarian carcinoma. J Biol Chem, 2002, 277: 245842-24593. 被引量:1

共引文献9

同被引文献32

引证文献6

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部